Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 129,600 shares of the company’s common stock with a per share exercise price of $24.12, the closing trading price on the grant date, and 64,800 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
